119 patents
Page 2 of 6
Utility
Treatment of B cell cancers using a combination comprising Btk inhibitors
18 Jul 23
Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent.
Nan Hu, Lai Wang, Jing Song, Tong Zhang, Kang Li, Lusong Luo, Min Wei, Zhiwei Wang, Yunhang Guo
Filed: 18 Aug 17
Utility
PYRIDO[2,3-B][1,4]OXAZINES or TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES As Iap Antagonists
13 Jul 23
Jing LI, Fengtao SONG, Zhiwei WANG
Filed: 3 Jun 21
Utility
Methods of Cancer Treatment Using ANTI-OX40 Antibodies In Combination with ANTI-PD1 or ANTI-PDL1 Antibodies
6 Jul 23
Provided are methods of treating cancer or increasing, enhancing, or stimulating an immune response with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD 134, or TNFRSF4), in combination with an anti-PD 1 or with an anti-PDL 1 antibody.
Beibei JIANG, Ye LIU, Xiaomin SONG
Filed: 19 Nov 20
Utility
Heterocyclic Compounds As Sting Modulators
6 Jul 23
Disclosed herein are heterocyclic compounds that may be used as STING modulators, the process for synthesis and to the use of such compounds in treatment of various diseases including cancers.
Jing LI, Sanjia XU, Zhiwei WANG, Guoliang ZHANG, Ce WANG, Jianzhuang MIAO, Lina GU, Gang CHEN, Xiaosong YU
Filed: 27 May 21
Utility
TYK-2 Inhibitor
25 May 23
Disclosed herein is a compound of Formula (I) for inhibiting TYK2 and treating disease associated with undesirable tyk-2 activity (tyk-2 related diseases), a method of using the compounds disclosed herein for treating inflammatory or autoimmune disease, and a pharmaceutical composition comprising the same.
Qiuwen WANG, Yunhang GUO, Zhiwei WANG
Filed: 25 Feb 21
Utility
BCL-2 Inhibitor
25 May 23
Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.
Hai XUE, Yunhang GUO, Zhiwei WANG
Filed: 14 Apr 21
Utility
Oral Capsule and Preparation Method Therefor
18 May 23
An oral capsule and a method for filling a capsule after directly mixing powders, the oral capsule comprising a composition for the oral capsule and a capsule shell, the composition for the oral capsule comprising zanubrutinib, a filler, a disintegrant, a wetting agent, a glidant, a lubricant, and optionally a binder.
Yiping WANG, Yuanjing GUO
Filed: 20 Jan 23
Utility
Co-administration of Mirdametinib and Lifirafenib for Use In Treating Cancers
27 Apr 23
The present disclosure relates to methods of treating cancers comprising coadministration of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, to a patient in need thereof.
Lusong LUO, Zhiyu TANG, Badreddin EDRIS, Todd Webster SHEARER
Filed: 2 Apr 21
Utility
Interoperable platform for reducing redundancy in medical database management
25 Apr 23
Systems and methods are disclosed for reducing redundancy in medical database management.
Geoffrey Kim, Bobby Y. Reddy, Joel Choi Park, Rajuli Lail
Filed: 31 May 22
Utility
Methods of Treating DLBCL Using BTK Inhibitors and Combinations Thereof
23 Mar 23
It provides methods of treating no-GCB DLBCL with (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4, 5, 6, 7-tetrahydropyrazolo-[1, 5-a] pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof.
Yiling YU, Yang LIU, Weige WANG, Hui YAO, Xinfeng HOU, Haiyi GUO, Zhirong SHEN, Lai WANG
Filed: 25 Feb 21
Utility
Immunotherapy for hepatocellular carcinoma
7 Mar 23
Disclosed herein is method for the prevention, delay of progression or treatment of hepatocellular carcinoma in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of an anti-PD-1 antibody, which is an antibody or a fragment antigen binding thereof, specifically binding to human PD-1.
Lai Wang, Kang Li, Qinzhou Qi, Jeannie Hou, Zhong Wu
Filed: 26 Jun 18
Utility
Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
28 Feb 23
The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Zhiwei Wang, Yunhang Guo, Gongyin Shi, Lai Wang
Filed: 10 May 22
Utility
CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF
23 Feb 23
The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Zhiwei WANG, Yunhang GUO, Gongyin SHI
Filed: 2 Sep 22
Utility
Treatment of Cancer with ANTI-OX40 Antibodies and Multi-kinase Inhibitors
26 Jan 23
The present disclosure provides methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a multi-kinase inhibitor.
Beibei JIANG, Ye LIU, Xiaomin SONG
Filed: 19 Nov 20
Utility
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS
19 Jan 23
Zhiwei WANG, Yunhang GUO
Filed: 3 Sep 21
Utility
Interoperable Platform for Reducing Redundancy In Medical Database Management
19 Jan 23
Systems and methods are disclosed for reducing redundancy in medical database management.
Geoffrey KIM, Bobby Y. REDDY, Joel Choi PARK, Rajuli Lall
Filed: 31 May 22
Utility
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
17 Jan 23
Yunhang Guo, Desheng Yu, Zhiwei Wang
Filed: 25 Jan 18
Utility
Methods of Cancer Treatment Using ANTI-OX40 Antibodies In Combination with PI3 Kinase Delta Inhibitors
12 Jan 23
Provided are methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a PI3K (phosphatidylinositol-4,5-bis-phosphate 3-kinase) delta inhibitor.
Beibei JIANG, Ye LIU, Jing LI, Xiaomin SONG
Filed: 19 Nov 20
Utility
Bcl-2 INHIBITORS
5 Jan 23
Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.
Hai XUE, Yunhang GUO, Zhiwei WANG
Filed: 27 Oct 20
Utility
Methods of Cancer Treatment with ANTI-OX40 Antibody In Combination with Chemotherapeutic Agents
5 Jan 23
Provided are methods of treating cancer with non-competitive, anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a chemotherapeutic agent.
Beibei JIANG, Ye LIU, Xiaomin SONG
Filed: 19 Nov 20